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The role of the Y chromosome in oncogenesis of human
cancers has been somewhat controversial. Both gain and
loss of the Y chromosome in different leukemia, lym-
phoma, and solid tumors have been reported (Abeliovich
et al. 1994; Brothman 1997; Dave et al. 1996; Geburek
et al. 1997; Jackson-Cook et al. 1996; Kirk et al. 1994;
Konig et al. 1994; Mertens et al. 1997; Riske et al. 1994;
Watanabe et al. 1996). Conceivably, both oncogenes and
tumor-suppressor genes exist on this chromosome, and
they may act at different points during tumorigenesis,
particularly for cancers of male-specific organs, such as
the testis and the prostate. One scenario suggests that
aberrant expression of an oncogene favoring cell pro-
liferation may activate the early stages of tumorigenesis.
These early events may be mediated by the duplication
of all or part of the Y chromosome. The loss or repres-
sion of a tumor-suppressor gene may be essential for the
tumor to acquire aggressive properties at later stages of
cancer progression, possibly triggered by the loss of the
Y chromosome. Unfortunately, most studies that have
tried to define the role of the Y chromosomal loci in
human cancers have relied on purely cytogenetic tech-
niques—either classical or molecular.Many genomewide
linkage studies have excluded the Y chromosome from
their analyses (Cooney et al. 1997; Dunsmuir et al. 1998;
Murray et al. 1994; Xu et al. 1998), since the bulk of
the Y chromosome neither pairs with, nor recombines
with, the X chromosome during meiosis. Hence, iden-
tification of oncogenic and tumor-suppressor loci on this
chromosome has been lacking. Despite these difficulties,
one cancer predisposition locus has been assigned to this
chromosome—namely, the gonadoblastoma locus on the
Y chromosome (GBY).
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Genes on the Human Y Chromosome
Recent progress in positional cloning of Y-linked genes
has provided a pool of candidate genes for gonado-
blastoma. The 33 functional genes that are currently
recognized on this chromosome (fig. 1) may be divided
into three distinct groups. The first group consists of X-
Y identical genes that are located on one of the two
pseudoautosomal regions (PARs). PAR1 is situated on
the telomere of the short arm and contains ∼2.6 Mb of
DNA. It harbors 10 genes that act in numerous path-
ways, including bone growth, cytokine signaling, cellular
energy metabolism, melatonin synthesis, and cell surface
antigen expression. PAR2, situated on the telomere of
the long arm, contains 400 kb of DNA and includes two
genes that encode an interleukin receptor and a synap-
tobrevin-like protein. Each gene in the PARs corresponds
to an identical gene in the PARs of the X chromosome.
A second group consist of X-Y homologous—but not
identical—genes that are located on the nonrecombining
region on the short and long arms of the Y chromosome.
There are 10 single-copy genes in this group, most of
which are ubiquitously expressed in many human tis-
sues, including those of the testis and the prostate. It is
still uncertain whether these X- and Y-homologous genes
are functionally interchangeable. The third group in-
cludes 11 genes on the nonrecombining region. Except
for the sex-determining region Y (SRY), all these genes
are repeated on the Y chromosome. Some are candidates
for the azoospermia factor (AZF; see McElreavey and
Krausz (1999) [in this issue]). Exact functions for most
of the genes on the nonrecombining region of the Y
chromosome are still uncertain. Those that encode cy-
tokine receptors, transcription factors, protein kinase,
and phosphatase may influence cell proliferation and/or
signal transduction and are good candidates for further
studies on their probable involvement in oncogenesis of
human and/or male-specific cancers.
Candidate Genes for the Gonadoblastoma Locus
Gonadoblastomas are gonadal neoplasms that consist
of aggregates of germ cells and sex cord elements (Scully
1953, 1970). Although such tumors are rarely, if ever,
found in normal males or females, in 46,XY testicular
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Figure 1 Genes on the human Y chromosome. This map rep-
resents an updated version of a figure presented at the Third Inter-
national Workshop on Y Chromosome Mapping (Vogt et al. 1997).
The Lahn-Page column indicates genes recently isolated by these in-
vestigators (Lahn and Page 1997). Other entries were derived from
respective reports (Gianfrancesco et al. 1998; Ried et al. 1998; Esposito
et al. 1999). The deletion intervals are drawn only approximately to
the cytogenetic locations. See Vollrath et al. (1992) and Lahn and Page
(1997) for a more precise assignment of deletion intervals.
feminization (Tfm) patients, or in 47,XXY or 46,XX
males (all of whose testes are devoid of germ cells), gon-
adoblastomas develop in 130% of phenotypic females
who harbor some Y-chromosomal materials in their ge-
nome (Verp and Simpson 1987; Sultana et al. 1995;
Iezzoni et al. 1997). On the basis of these observations,
Page (1987) postulated the existence of a GBY locus,
on the Y chromosome, that predisposes the dysgenetic
gonads of XY sex-reversed females to develop gona-
doblastoma. Page further hypothesized that GBY acts as
an oncogene only in the dysgenetic gonad and has a
normal function in the testis. Since gonadoblastomas
recapitulate germ cell/support cell architecture, Page sug-
gested that GBY might well function in or prior to sper-
matogenesis of the normal testis.
The mapping of the underlying gene for this condition
has proved unexpectedly complex. Using a panel of
DNAs from sex-reversed and gonadoblastoma patients,
Page had initially mapped the GBY locus to deletion
intervals 3 on the short arm and 4B–7 on the long arm
of this chromosome (fig. 1; also see Page 1987). Sub-
sequent studies by Tsuchiya et al. (1995) further sub-
localized the GBY locus to a small region at intervals
3E–3G proximal to and 4B at the centromere. These
investigators estimated the GBY critical region to be
∼1–2 Mb on the short arm of the human Y chromosome
(fig. 1, dotted area on Yp). Salo et al. (1995), however,
mapped the GBY locus within 4 Mb of DNA between
intervals 4B at and 5E proximal to the centromere on
the long arm of the Y chromosome.
These various findings led Tsuchiya et al. (1995) to
speculate that more than one gene may be implicated in
gonadoblastoma, and it is also possible that some rel-
evant gene is present in multiple copies that are distrib-
uted across the Y chromosome. However, it remains un-
certain whether the discrepancy between regions for
GBY sublocalized by the two groups arose because of
inversion polymorphisms on the Y chromosome (Vogt
et al. 1997). Despite the elusive location of GBY, the
isolation of many of the Y chromosome genes (Lahn and
Page 1997; Vogt et al. 1997) has provided a pool of
candidates for GBY.
The small region defined by Tsuchiya et al. (1995)
contains seven known genes: amelogenin Y (AMELY),
RNA binding motif (RBM), protein kinase Y (PRKY),
protein tyrosine phosphatase (PTP)-BL related Y (PRY),
testis transcripts Y1 and Y2 (TTY1 and TTY2), and
testis-specific protein Y-encoded (TSPY). BothTTY1 and
TTY2 consist of repetitive DNA sequences, and their
transcripts lack any apparent protein-coding sequences
(Lahn and Page 1997), so these genes may serve no cru-
cial function. AMELY, like its X-linked homologue,
AMELX, encodes an enamel protein (Lau et al. 1989)
that is exclusively expressed in the developing tooth bud
(Salido et al. 1992). Hence, neither of these gene prod-
ucts is likely to affect cell proliferation in the gonad.
RBM is a repeated gene with functional sequences that
are mostly located in interval 6 on the long arm (Ma et
al. 1993). Only a few copies are located within the GBY
critical region. The RBM protein contains an RNA-bind-
ing motif, from which it derives its name, and it localizes
primarily to the nuclei of spermatogenic cells (Elliott et
al. 1997). As discussed by McElreavey and Krausz
(1999), RBM is postulated to act in the nuclear metab-
olism of newly synthesized RNA (Elliott et al. 1998) and
may underlie the azoospermia defect that has been
mapped to interval 6 (Ma et al. 1993; Vogt et al. 1997).
Although its transcripts have been detected in gonadob-
lastoma tissues (Tsuchiya et al. 1995), RBM is an un-
likely candidate for GBY, since most of its functional
units are located outside the GBY critical region. PRKY
and its X homologue, PRKX, encode members of the
cAMP-dependent serine/threonine protein kinase family
(Klink et al. 1995; Schiebel et al. 1997). PRY is a newly
identified repeated gene whose product displays some
similarity to PTP-BL (Lahn and Page 1997). Other cop-
ies of PRY are found in interval 6, outside the GBY
critical region.
Currently, we cannot exclude the possibility that mu-
tation and/or aberrant expression of PRKY or PRY are
responsible for the predisposition of the dysgenetic go-
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nads of XY females to gonadoblastoma. Protein kinases
often act as signal transducers for growth factor and
cytokine receptors, whereas phosphatases counterbal-
ance their effects (see Hunter 1998a, 1998b, for review).
Indeed, there is ample precedent that activated protein
kinases can serve as oncoproteins and that protein phos-
phatases can act to suppress tumor formation (see,
e.g., Myers and Tonks 1997). Hence, either PRKY or
PRY may possess growth-regulatory functions, but the
biological functions of these proteins are not yet
understood.
The remaining candidate locus for gonadoblastoma is
TSPY, a multicopy gene that is located primarily in the
GBY critical region at interval 3, as defined by deletion
mapping (Arnemann et al. 1987, 1991; Zhang et al.
1992; Vogt et al. 1997). Several homologous copies have
also been mapped on proximal intervals 4 and 5 on the
long arm. TSPY expression has been detected in gona-
doblastoma tissues (Tsuchiya et al. 1995). Significantly,
as detailed below, recent studies provide circumstantial
evidence supporting a role for TSPY as an oncogene.
For this reason, TSPY has emerged as the most likely
candidate for GBY.
TSPY Is Evolutionarily Conserved on the Mammalian
Y Chromosome
Approximately 20–40 copies of TSPY or of similar
sequences cluster at two locations—TSPYA and
TSPYB—within interval 3 on the short arm of the human
Y chromosome (Vogt et al. 1997). Additional copies are
also present in interval 4/5 on the long arm. Each copy
of the gene consists of six exons distributed over 2.8 kb
(Schnieders et al. 1996) and is embedded in a 20-kb
tandemly repeated unit (Zhang et al. 1992; Manz et al.
1993). The number of functional units in this array is
uncertain, but, in most cases, 35–45-kb DNA fragments
from the region direct the expression of a normal-sized
TSPY transcript in transfected cells (Zhang et al. 1992).
Hence, all necessary cis-acting transcription and RNA-
processing signals appear to be present in most TSPY
repeat units.
Homologues of TSPY also map to the Y chromosome
in other mammals, including primates, artiodactyls, and
rodents (Conrad et al. 1996; Kim et al. 1996; Vogel et
al. 1997, 1998a; Glaser et al. 1998; Mazeyrat and
Mitchell 1998), and in all cases these genes exhibit a
similar structural organization (Vogel et al. 1997; Ma-
zeyrat and Mitchell 1998). Two functional copies of
Tspy are found on the rat Y chromosome (Mazeyrat and
Mitchell 1998), although the mouse carries only a single,
poorly expressed copy of the Tspy gene, which contains
numerous in-frame stop codons within its coding se-
quence. This sequence almost certainly represents a pseu-
dogene (Mazeyrat and Mitchell 1998; Vogel et al.
1998a), but other related cDNAs have recently been iso-
lated from both human and mouse (Vogel et al. 1998b),
and one or more homologous genes may function in
place of the Y-linked Tspy in the mouse.
Normal and Abnormal Expression of TSPY in the
Testis
TSPY transcripts have also been detected in fetal testis
as early as the 22d week of gestation in humans (Zhang
et al. 1992), and expression persists through adulthood.
TSPY occurs in the adult testis as a 33-kD protein and
as a phosphoprotein with an apparent molecular weight
of 38 kD (Schnieders et al. 1996; author’s unpublished
data). Immunohistological staining with a specific an-
tibody localizes the TSPY epitope primarily to the cy-
toplasm of a subset of spermatogonial cells and around
the basal lamina of the seminiferous tubules of the adult
testis (Schnieders et al. 1996). Interestingly, spermato-
gonial cells that express TSPY appear to be paired with
adjacent cells that show lower expression. TSPY signals
are also observed in the nuclei of a relatively small pro-
portion of spermatogonial cells. Schnieders et al. (1996)
hypothesize that TSPY regulates the normal prolifera-
tion of spermatogonia and marks the entry of the sper-
matogonia into the meiotic differentiation. Significantly,
TSPY is detected with higher intensity in spermatogonia
at early stages of testicular tumorigenesis, in carcinoma
in situ of the testis (Schnieders et al. 1996), and in sem-
inomas (fig. 2). These results suggest that TSPY is aber-
rantly expressed in tumors with germ cell origins. Con-
versely, XY females, who exhibit Tfm as a result of
mutations in the androgen-receptor gene, show positive
TSPY staining in a much-reduced number of residual
spermatogonia in their testes. Hence, TSPY expression
appears to depend on spermatogenic activity and a
proper hormonal environment. This postulate is reason-
able since spermatogenesis is greatly influenced by male
hormones (see reviews, McLachlan et al. 1996; Yong et
al. 1988). If TSPY indeed serves a vital function in di-
recting the spermatogonial stem cells to enter meiotic
division, it is conceivable that its expression is regulated
by androgen and androgen receptor.
Aberrant Expression of TSPY in Prostate
The testis-specific expression that inspired the naming
of TSPY (Arnemann et al. 1987, 1991) is not absolute.
Expression in somatic cells was not considered in our
initial study, although we detected specific transcripts
from this gene in a highly metastatic melanoma cell line,
HT-144, derived from a 29-year-old male patient (Zhang
et al. 1992). The observation of TSPY in testicular tu-
mors has now led us to reexamine the expression of this
gene in other male-specific cancers, such as those of the
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Figure 2 Localization of TSPY on tumor cells of human seminoma specimens by immunostaining. A highly specific antibody against a
recombinant TSPY protein (Zhang et al. 1992) was used in immunostaining with two human seminoma specimens (Ko¨mu¨ves et al. 1998). A
secondary antibody conjugated with the alkaline phosphatase was used for visualization of TSPY protein locations (red). The slides were
counterstained with hematoxylin-eosin (greenish blue). A, Specific signals were observed on the cancerous region (e.g., boxed area) which, under
higher magnification as in B, showed specific antibody staining of the large seminoma cells with characteristic vesicular nuclei. C, A second
specimen showing specific immunostaining of TSPY protein in both cytoplasm (open arrows) and nucleus (solid arrows) of the tumor cells. Bar
represents 200 mm in A and 25 mm in B and C.
prostate. Using both in situ mRNA hybridization and
immunostaining techniques, we have demonstrated a
preferential expression of TSPY in the epithelial cells at
the cancerous regions of prostate cancers of high and
low Gleason grades (Y.-F. C. Lau and L. G. Ko¨mu¨ves,
unpublished data). These findings strongly suggest that
aberrant expression of TSPY may also be involved in
tumorigenesis of the prostate gland. Further, we also
observed an up-regulation of TSPY expression in the
responsive prostatic cell line, LNCaP, with stimulation
by androgen (Y.-F. C. Lau and J. Q. Zhang, unpublished
data). These latter results further support the hypothesis
that TSPY (or some copies of its functional units) is
regulated by male hormone and its receptor in the pros-
tate as well as the testis.
TSPY, the SET Oncoprotein, and Other Cyclin
B–Binding Proteins
The involvement of TSPY in cell proliferation and
tumorigenesis is further reinforced by its homology to
the SET oncogene on 9q34. SET was initially identified
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in a patient with acute undifferentiated leukemia, who
harbored an intrachromosomal translocation on chro-
mosome 9 (von Lindern et al. 1992). This translocation
fused the 3′ end of c-SET with another oncogene, CAN,
to create a SET-CAN chimera that encodes a 155-kD
putative oncoprotein. The two normal c-SET transcripts
of 2.0 and 2.7 kb differ only in their 3′ untranslated
domains and are predicted to encode an identical 32-
kD protein. Immunoprecipitation analysis demonstrates
that c-SET is a nuclear phosphoprotein of 39 kD that
is widely expressed in numerous tissues and cell types
(Adachi et al. 1994), including the testis.
SET has also been identified as the template-activating
factor, TAF-1 (Nagata et al. 1995), and as a potent in-
hibitor of protein phosphatase 2A (PP2A; Li et al. 1996).
TAF-1 was defined because of its role in stimulating in-
itiation and elongation in adenovirus core DNA. PP2A
is an abundant, multifunctional serine/threonine–specific
phosphatase that stimulates the replication of both SV40
DNA replication and chromosomal DNA (Lin et al.
1998). PPA2 antagonizes cdc2/cyclin B complexes,
which regulate the progression of cells past the G2 stage
of the cell cycle; hence, inhibition of PPA2 and cessation
of DNA replication may be required for the onset of
mitotic division. Indeed, Kellogg et al. (1995) have dem-
onstrated that SET and related proteins, such as nucle-
osome assembly protein 1 (NAP-1), interact specifically
with mitotic cyclin B. Hence, SET may serve a normal
function in cell cycle regulation, and its fusion with CAN
may generate an oncogenic protein that promotes leu-
kemic cell proliferation.
The homology of TSPY with SET was initially noted
by Tsuchiya et al. (1995) and subsequently characterized
by Schnieders et al. (1996). Currently, there are 23 mem-
bers of the SET/NAP-1 family of cyclin B–binding pro-
teins, as defined by their homologies to a 194-residue
conserved domain. The TSPY proteins share homology
to the amino half of this consensus domain, whereas the
SET homology extends 42 additional residues toward
the carboxyl terminus. Along with the homology be-
tween these classes of proteins, the fact that TSPY and
SET proteins are of similar molecular weights and exist
as phosphoproteins (Adachi et al. 1994; Schnieders et
al. 1996; J. Zhang and Y.-F. C. Lau, unpublished data)
make it tempting to speculate that TSPY serves a spe-
cialized role in the testis, related to that of SET. Prelim-
inary studies conducted in our laboratory suggest that
TSPY binds to human cyclin B and is phosphorylated
by p34cdc2/cyclin B complex in vitro (J. Zhang and Y.-
F. C. Lau, unpublished data). These observations, if con-
firmed in vivo, would further support the model that
interactions between TSPY and cyclin B direct sper-
matogonia to enter meiosis.
Is TSPY an Oncogene?
TSPY possesses several interesting features that fit the
profile for the long-sought gonadoblastoma gene. First,
most of its repeat units have been mapped to the GBY
critical region(s), including intervals 3E–3G and 4/5
(Page 1987; Salo et al. 1995; Tsuchiya et al. 1995). Sec-
ond, its expression in spermatogonial cells in normal
testis (Schnieders et al. 1996) suggests a function early
in spermatogenesis, as predicted by Page (1987) in his
original hypothesis. Third, TSPY is up-regulated in gon-
adoblastoma tissues (Tsuchiya et al. 1995), as well as in
certain testicular and prostate cancers (Schnieders et al.
1996; Y.-F. C. Lau and L. G. Ko¨mu¨ves, unpublished
data). Finally, TSPY expression is drastically reduced in
the dysgenetic gonads of patients with 46,XY Tfm, who
rarely develop gonadoblastomas.
If TSPY is an oncogene, how might it contribute to
development of gonadoblastoma or testicular or prostate
cancer? Given the multiplicity of TSPY genes on the Y
chromosome, it is difficult to envision how the mutation
of a single copy of the gene could confer oncogenic po-
tential, although such a strong, dominantly acting mu-
tation is conceivable.More likely, the oncogenic function
of TSPY may be explained by its aberrant or inappro-
priate expression either in somatic cells (e.g., epithelial
cells of the prostate) that are incapable of entering mei-
otic differentiation or in germ cells (e.g., dysgenetic
gonads) that are in an environment unsuitable for
spermatogenesis.
The reason for such aberrant expression is currently
unknown. If TSPY is indeed regulated by androgen and
its receptor, misexpression could result either from mu-
tations within the regulatory elements of one or a few
of its transcriptional units or from inappropriate sig-
naling, perhaps prompted by changes in the hormonal
environment in the testis or prostate. The aberrant ex-
pression of TSPY, however, only predisposes the dys-
genetic gonads (in gonadoblastoma), abnormal sper-
matogonia (in testicular cancer), or somatic epithelial
cells (in prostate cancer) to other oncogenic events in
the multistep process of carcinogenesis (Knudson 1997).
TSPY may contribute to such predisposition by poten-
tiating cell proliferation. This hypothesis provides a basis
for further evaluation of TSPY as a potential Y-linked
proto-oncogene.
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